ArticleFrontiers in cellular and infection microbiology2025
Metabolomics and lipidomics of plasma biomarkers for tuberculosis diagnostics using UHPLC-HRMS.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid metabolism in the resuscitation of dormant mycobacterium tuberculosis: molecular resilience, host hijacking, and clinical opportunities.Frontiers in cellular and infection microbiology · 2026Review
- Role of Lipidomics in Respiratory Tract Infections: A Systematic Review of Emerging Evidence.Microorganisms · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Determining metabolic profiles during host-pathogen interactions is crucial for developing novel diagnostic tests and exploring the mechanisms underlying infectious diseases. However, the characteristics of the circulating metabolites and their functions after Methods: Seventy-two TB patients and 78 healthy controls (HCs) were recruited as the training set, while 30 TB patients and 30 HCs were enrolled as the independent validation set. Metabolites in plasma samples were analyzed by high-resolution mass spectrometry. Differential metabolites were screened using principal component analysis and machine learning algorithms including LASSO, Random Forest, and XGBoost. The diagnostic accuracy of the core differential metabolites was evaluated. Pearson correlation analysis was performed. Result: The metabolic profiling of TB patients showed significant separation from that of the HCs. In the training set, 282 metabolites were identified as differentially expressed in TB patients, with 214 metabolites validated in the independent validation cohort. KEGG pathway enrichment analysis showed that the differential metabolites were mainly enriched in lipid metabolism. Seven core differential metabolites were identified by the three machine learning algorithms. Receiver operating characteristic analysis revealed that Angiotensin IV had high accuracy in diagnosing TB. Conclusion: These newly identified plasma metabolites are expected to serve as potentially valuable biomarkers for TB, potentially facilitating the diagnosis of the disease and enhancing the understanding of its underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.